Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMV Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRINCETON, N.J., AUG. 07, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (PMV PHARMA OR THE COMPANY; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., MAY 23, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (PMV PHARMA; NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT DAVID H. MACK, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER AND DEEPIKA JALOTA, PHARM. D., CHIEF DEVELOPMENT OFFICER, WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES. MANAGEMENT WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

PMV PHARMACEUTICALS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

ENROLLMENT ON TRACK IN PHASE 2 PIVOTAL PORTION OF PYNNACLE CLINICAL TRIAL EVALUATING REZATAPOPT AS MONOTHERAPY IN PATIENTS WITH TP53 Y220C AND KRAS WILD-TYPE ADVANCED SOLID TUMORS; MORE THAN 90% OF SITES ACTIVATED ACROSS THE U.S., EUROPE, U.K., AND ASIA-PACIFIC; INTERIM ANALYSIS DATA EXPECTED MID-2025 ENROLLMENT COMMENCED IN THE MD ANDERSON CANCER CENTER INVESTIGATOR-INITIATED PHASE 1B STUDY EVALUATING REZATAPOPT MONOTHERAPY AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY AML/MDS HARBORING A TP53 Y220C MUTATION CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $183.3 MILLION AS OF DECEMBER31, 2024 PROVIDING EXPECTED CASH RUNWAY TO END OF 2026 PRINCETON, N.J., MARCH 03, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY CLINICAL-STAGE COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER31, 2024, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., FEB. 11, 2025 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT DAVID H. MACK, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER AND DEEPIKA JALOTA, PHARM. D., CHIEF DEVELOPMENT OFFICER, WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES. MANAGEMENT WILL ALSO PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

PRINCETON, N.J., MAY 09, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., MARCH 27, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE REGISTRATIONAL, TUMOR-AGNOSTIC PYNNACLE PHASE 2 TRIAL OF REZATAPOPT (PC14586) IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING A TP53 Y220C MUTATION AND KRAS WILD-TYPE (WT). REZATAPOPT IS A FIRST-IN-CLASS PRECISION ONCOLOGY SMALL MOLECULE INVESTIGATIONAL THERAPY THAT SELECTIVELY TARGETS MUTATED P53 Y220C PROTEINS IN SOLID TUMORS.

PMV PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN GLOBAL TUMOR-AGNOSTIC PHASE 2 PYNNACLE TRIAL FOR REZATAPOPT IN TP53 Y220C-POSITIVE SOLID TUMORS

PRINCETON, N.J., MARCH 18, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED THAT A PHASE 1 ANALYSIS REPORTED PROMISING ANTI-TUMOR ACTIVITY OF REZATAPOPT (PC14586) IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED OVARIAN CANCER HARBORING A TP53 Y220C MUTATION. REZATAPOPT IS A FIRST-IN-CLASS PRECISION ONCOLOGY SMALL MOLECULE INVESTIGATIONAL THERAPY THAT SELECTIVELY TARGETS THE TP53 Y220C MUTATION IN SOLID TUMORS.

PMV PHARMACEUTICALS PYNNACLE PHASE I DATA OF REZATAPOPT IN ADVANCED OVARIAN CANCER FEATURED IN LATE-BREAKING ORAL PRESENTATION AT 2024 SGO ANNUAL MEETING ON WOMEN'S CANCER

PRINCETON, N.J., FEB. 29, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC. (NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR-AGNOSTIC THERAPIES TARGETING P53, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2023, AND PROVIDED A CORPORATE UPDATE.

PMV PHARMACEUTICALS REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

PRINCETON, N.J., JAN. 18, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED A STRATEGIC REDUCTION OF ITS WORKFORCE BY APPROXIMATELY 30%. PMV WILL MAINTAIN A FOCUSED DISCOVERY RESEARCH EFFORT AND EXPECTS THAT THE RESULTING SAVINGS IN OPERATING EXPENSES WILL EXTEND ITS CASH RUNWAY TO THE END OF 2026.

PMV PHARMACEUTICALS ANNOUNCES PRIORITIZATION OF PC14586 CLINICAL DEVELOPMENT AND EXTENDED CASH RUNWAY

PRINCETON, N.J., JAN. 05, 2024 (GLOBE NEWSWIRE) -- PMV PHARMACEUTICALS, INC.(NASDAQ: PMVP), A PRECISION ONCOLOGY COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE, TUMOR AGNOSTIC THERAPIES TARGETING P53, TODAY ANNOUNCED KEY APPOINTMENTS ACROSS ITS LEADERSHIP TEAM. THESE INCLUDE:

PMV Pharmaceuticals, Inc.

PMVP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PMV Pharmaceuticals, Inc.

PMVP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PMVP